Please wait while the formulary information is being retrieved.
Drug overview for IMOVAX RABIES VACCINE (PF) (rabies vaccine, human diploid cell/pf):
Generic name: rabies vaccine, human diploid cell/PF (RAY-beez)
Drug class: Rabies Vaccines
Therapeutic class: Biologicals
Rabies vaccine is an inactivated virus vaccine that contains rabies virus antigens and is used to stimulate active immunity to rabies infection. Rabies vaccine is commercially available in the US as human diploid-cell rabies vaccine (HDCV; Imovax(R)) and purified chick embryo cell culture rabies vaccine (PCECV; RabAvert(R)).
Rabies vaccine is used to stimulate active immunity to rabies in adults, adolescents, and children. Rabies vaccine is used for preexposure vaccination in individuals at increased risk of exposure to the disease or virus and also is used for postexposure prophylaxis as part of a regimen that includes local wound treatment and active immunization with rabies vaccine and may also include passive immunization with rabies immune globulin (RIG) in certain patients. There currently are 2 types of rabies vaccine commercially available in the US: human diploid-cell rabies vaccine (HDCV; Imovax(R)) and purified chick embryo cell culture rabies vaccine (PCECV; RabAvert(R)). While experience with HDCV (Imovax(R)) is more extensive than that with PCECV (RabAvert(R)), clinical trials have demonstrated that the immunogenicity of PCECV is equivalent to that of HDCV.
Generic name: rabies vaccine, human diploid cell/PF (RAY-beez)
Drug class: Rabies Vaccines
Therapeutic class: Biologicals
Rabies vaccine is an inactivated virus vaccine that contains rabies virus antigens and is used to stimulate active immunity to rabies infection. Rabies vaccine is commercially available in the US as human diploid-cell rabies vaccine (HDCV; Imovax(R)) and purified chick embryo cell culture rabies vaccine (PCECV; RabAvert(R)).
Rabies vaccine is used to stimulate active immunity to rabies in adults, adolescents, and children. Rabies vaccine is used for preexposure vaccination in individuals at increased risk of exposure to the disease or virus and also is used for postexposure prophylaxis as part of a regimen that includes local wound treatment and active immunization with rabies vaccine and may also include passive immunization with rabies immune globulin (RIG) in certain patients. There currently are 2 types of rabies vaccine commercially available in the US: human diploid-cell rabies vaccine (HDCV; Imovax(R)) and purified chick embryo cell culture rabies vaccine (PCECV; RabAvert(R)). While experience with HDCV (Imovax(R)) is more extensive than that with PCECV (RabAvert(R)), clinical trials have demonstrated that the immunogenicity of PCECV is equivalent to that of HDCV.
DRUG IMAGES
IMOVAX RABIES VACCINE VIAL
The following indications for IMOVAX RABIES VACCINE (PF) (rabies vaccine, human diploid cell/pf) have been approved by the FDA:
Indications:
Rabies postexposure prophylaxis
Rabies vaccination
Professional Synonyms:
Hydrophobia postexposure prophylaxis
Hydrophobia prevention
Lyssa postexposure prophylaxis
Lyssa prevention
Lytta postexposure prophylaxis
Lytta prevention
Rabies post exposure prophylaxis
Rabies post-exposure prophylaxis
Rabies postexposure prevention
Rabies prophylaxis
Indications:
Rabies postexposure prophylaxis
Rabies vaccination
Professional Synonyms:
Hydrophobia postexposure prophylaxis
Hydrophobia prevention
Lyssa postexposure prophylaxis
Lyssa prevention
Lytta postexposure prophylaxis
Lytta prevention
Rabies post exposure prophylaxis
Rabies post-exposure prophylaxis
Rabies postexposure prevention
Rabies prophylaxis
The following dosing information is available for IMOVAX RABIES VACCINE (PF) (rabies vaccine, human diploid cell/pf):
Whenever possible, the rabies vaccine (HDCV; Imovax(R) or PCECV; RabAvert(R)) used for the initial dose should be used for subsequent doses in the vaccine series in the same individual. Although only limited data are available to date, most experts state that rabies vaccines available in the US may be considered interchangeable. The ACIP states that clinical studies are not available to date showing differences in efficacy or safety if the vaccine series is completed with a different preparation.
The recommended vaccination schedule should be adhered to as closely as possible. If a minor deviation from the schedule occurs (e.g., a dose is delayed by a few days), the dose should be given and the vaccination schedule should be resumed using the same interval between doses. If a substantial deviation from the schedule occurs, serologic testing should be performed 7-14 days after the final vaccine dose to assess immune status.
For the 2-dose preexposure prophylaxis vaccine series, when substantial delays occur (2 weeks or more) from the recommended date of the second dose, local and state public health authorities should be consulted for guidance.
When booster doses are necessary for preexposure vaccination in adults, adolescents, or children to ensure continuous protection against rabies, HDCV (Imovax(R)) or PCECV (RabAvert(R)) is administered IM in 1-mL doses.
The need for booster doses of rabies vaccine depends on the nature and category of risk associated with the potential exposure. (See Table 1.)
The recommended vaccination schedule should be adhered to as closely as possible. If a minor deviation from the schedule occurs (e.g., a dose is delayed by a few days), the dose should be given and the vaccination schedule should be resumed using the same interval between doses. If a substantial deviation from the schedule occurs, serologic testing should be performed 7-14 days after the final vaccine dose to assess immune status.
For the 2-dose preexposure prophylaxis vaccine series, when substantial delays occur (2 weeks or more) from the recommended date of the second dose, local and state public health authorities should be consulted for guidance.
When booster doses are necessary for preexposure vaccination in adults, adolescents, or children to ensure continuous protection against rabies, HDCV (Imovax(R)) or PCECV (RabAvert(R)) is administered IM in 1-mL doses.
The need for booster doses of rabies vaccine depends on the nature and category of risk associated with the potential exposure. (See Table 1.)
No enhanced Administration information available for this drug.
No dosing information available.
No generic dosing information available.
The following drug interaction information is available for IMOVAX RABIES VACCINE (PF) (rabies vaccine, human diploid cell/pf):
There are 0 contraindications.
There are 1 severe interactions.
These drug interactions can produce serious consequences in most patients. Actions required for severe interactions include, but are not limited to, discontinuing one or both agents, adjusting dosage, altering administration scheduling, and providing additional patient monitoring. Review the full interaction monograph for more information.
| Drug Interaction | Drug Names |
|---|---|
| Non-Live or Non-Replicating Vaccines/Teplizumab SEVERITY LEVEL: 2-Severe Interaction: Action is required to reduce the risk of severe adverse interaction. MECHANISM OF ACTION: Teplizumab may cause lymphopenia and alter the immune system's response to vaccines.(1) CLINICAL EFFECTS: Administration of a non-live vaccine within the 2 weeks prior to, during, or for 6 weeks following teplizumab therapy may result in decreased effectiveness of the vaccine.(1) PREDISPOSING FACTORS: None determined. PATIENT MANAGEMENT: Ideally, administer vaccines prior to initiating teplizumab therapy. The manufacturer of teplizumab states that non-live vaccines (e.g., inactivated or mRNA vaccines) are not recommended within the 2 weeks prior to, during, or for 6 weeks after stopping teplizumab therapy.(1) The immune response to non-live vaccines should be monitored in patients who receive teplizumab within these time frames. The Centers for Disease Control's (CDC) Advisory Committee on Immunization Practices (ACIP) states that non-live vaccines should be used with caution in patients who are severely immunosuppressed. Patients who are vaccinated within the 14 days prior to initiating immunosuppressive therapy should be considered unvaccinated and should be revaccinated at least 3 months after immunosuppressive therapy is discontinued when immune competence is restored.(2) For COVID-19 vaccines, the CDC advises planning for vaccination at least 2 weeks before starting or resuming immunosuppressive therapy. Patients should be offered and given a COVID-19 vaccine even if the use and timing of immunosuppressive agents cannot be adjusted. The CDC states that an age-appropriate mRNA COVID-19 vaccine is preferred over the Janssen COVID-19 vaccine for the primary and booster doses for immunocompromised patients. All immunocompromised patients over 5 years of age should receive at least 1 booster dose if eligible. See the CDC's Interim Clinical Considerations for Use of COVID-19 Vaccines for age- and product-specific recommendations.(3) DISCUSSION: Vaccinations may be less effective if administered within 2 weeks before, during, and for 6 weeks following teplizumab therapy.(1) |
TZIELD |
There are 8 moderate interactions.
The clinician should assess the patient’s characteristics and take action as needed. Actions required for moderate interactions include, but are not limited to, discontinuing one or both agents, adjusting dosage, altering administration.
| Drug Interaction | Drug Names |
|---|---|
| Non-Live or Non-Replicating Vaccines/Fingolimod SEVERITY LEVEL: 3-Moderate Interaction: Assess the risk to the patient and take action as needed. MECHANISM OF ACTION: Fingolimod is an immunosuppressant and may alter the immune system's response to vaccines.(1) CLINICAL EFFECTS: Administration of a vaccine during and for 2 months following fingolimod therapy may result in decreased effectiveness of the vaccine.(1,2) PREDISPOSING FACTORS: None determined. PATIENT MANAGEMENT: Ideally, administer vaccines prior to initiating fingolimod therapy. The immune response to non-live vaccines should be monitored in patients receiving fingolimod or who have received fingolimod in the previous two months. Vaccinations given during and for 2 months after stopping fingolimod therapy may need to be repeated.(1,2) The Centers for Disease Control's (CDC) Advisory Committee on Immunization Practices (ACIP) states that non-live vaccines should be used with caution in patients who are severely immunosuppressed. Patients who are vaccinated within the 14 days prior to initiating immunosuppressive therapy should be considered unvaccinated and should be revaccinated at least 3 months after immunosuppressive therapy is discontinued when immune competence is restored.(3) DISCUSSION: Vaccinations may be less effective during and for 2 months following fingolimod therapy(1) however they are considered safe to administer.(2) |
FINGOLIMOD, GILENYA, TASCENSO ODT |
| Non-Live or Non-Replicating Vaccines/Siponimod SEVERITY LEVEL: 3-Moderate Interaction: Assess the risk to the patient and take action as needed. MECHANISM OF ACTION: Siponimod is an immunosuppressant and may alter the immune system's response to vaccines.(2) CLINICAL EFFECTS: Administration of a vaccine during and for up to 1 month after discontinuation of siponimod therapy may result in decreased effectiveness of the vaccine. Siponimod treatment should be paused 1 week prior and for 4 weeks after vaccination.(2) PREDISPOSING FACTORS: None determined. PATIENT MANAGEMENT: Ideally, administer vaccines prior to initiating siponimod therapy. The immune response to non-live vaccines should be monitored in patients receiving siponimod or who have received siponimod in the previous week. Vaccinations given during and for up to 1 month after discontinuation of siponimod therapy may need to be repeated.(2) The Centers for Disease Control's (CDC) Advisory Committee on Immunization Practices (ACIP) states that non-live vaccines should be used with caution in patients who are severely immunosuppressed. Patients who are vaccinated within the 14 days prior to initiating immunosuppressive therapy should be considered unvaccinated and should be revaccinated at least 3 months after immunosuppressive therapy is discontinued when immune competence is restored.(3) DISCUSSION: Vaccinations may be less effective if administered during and for up to 1 month after siponimod treatment(2) however they are considered safe to administer.(1) |
MAYZENT |
| Non-Live or Non-Replicating Vaccines/Satralizumab SEVERITY LEVEL: 3-Moderate Interaction: Assess the risk to the patient and take action as needed. MECHANISM OF ACTION: Satralizumab is an immunosuppressant and may alter the immune system's response to vaccines.(1) CLINICAL EFFECTS: Administration of a vaccine during satralizumab therapy may result in decreased effectiveness of the vaccine. If possible, non-live vaccines should be administered at least two weeks prior to initiation of satralizumab.(1) PREDISPOSING FACTORS: None determined. PATIENT MANAGEMENT: Ideally, administer vaccines two weeks prior to initiating satralizumab therapy. The immune response to non-live vaccines should be monitored in patients receiving satralizumab. Vaccinations given during satralizumab therapy may need to be repeated.(1) Patients who are vaccinated within the 14 days prior to initiating immunosuppressive therapy should be considered unvaccinated and should be revaccinated at least 3 months after immunosuppressive therapy is discontinued when immune competence is restored.(2) DISCUSSION: Vaccinations may be less effective if administered during satralizumab treatment.(1) |
ENSPRYNG |
| Non-Live or Non-Replicating Vaccines/Ublituximab SEVERITY LEVEL: 3-Moderate Interaction: Assess the risk to the patient and take action as needed. MECHANISM OF ACTION: Ublituximab is an immunosuppressant and may alter the immune system's response to vaccines.(1) CLINICAL EFFECTS: Administration of a non-live vaccine within 2 weeks before or during ublituximab therapy may result in decreased effectiveness of the vaccine. If possible, non-live vaccines should be administered at least two weeks prior to initiating ublituximab therapy.(1) PREDISPOSING FACTORS: None determined. PATIENT MANAGEMENT: Ideally, administer non-live vaccines at least two weeks prior to initiating ublituximab therapy. The immune response to non-live vaccines should be monitored in patients receiving ublituximab. Vaccinations given during ublituximab therapy may need to be repeated.(1) Patients who are vaccinated within the 14 days prior to initiating immunosuppressive therapy should be considered unvaccinated and should be revaccinated at least 3 months after immunosuppressive therapy is discontinued when immune competence is restored.(2) DISCUSSION: Vaccinations may be less effective if administered within 2 weeks before or during ublituximab treatment.(1) |
BRIUMVI |
| Systemic Corticosteroids; Corticotropin/Non-Live or Non-Replicating Vaccines SEVERITY LEVEL: 3-Moderate Interaction: Assess the risk to the patient and take action as needed. MECHANISM OF ACTION: Corticosteroids and corticotropin suppress the immune system and may alter the immune system's response to vaccines.(1) CLINICAL EFFECTS: Vaccines administered during or within 2 weeks prior to therapy with corticosteroids or corticotropin may result in decreased effectiveness of the vaccine.(1) PREDISPOSING FACTORS: Patients receiving immunosuppressive doses of corticosteroids or corticotropin for equal to or greater than 14 consecutive days.(1) PATIENT MANAGEMENT: The Centers for Disease Control's (CDC) Advisory Committee on Immunization Practices (ACIP) states that non-live vaccines should be used with caution in patients who are severely immunosuppressed, including those who are receiving or have received high-dose, systemic steroids for greater than or equal to 14 consecutive days. When initiating immunosuppressives doses of corticosteroids, wait 2 weeks after a non-live vaccines is administered. However, if patients require therapy for chronic inflammatory conditions, do not delay therapy due to past vaccines.(1) The immune response to non-live vaccines should be monitored in patients receiving corticosteroids. Vaccinations given during corticosteroid therapy may need to be repeated.(1) Patients who are vaccinated within the 14 days prior to initiating immunosuppressive therapy should be considered unvaccinated and should be revaccinated at least 3 months after immunosuppressive therapy is discontinued when immune competence is restored.(1) DISCUSSION: Vaccinations given during and within 2 weeks prior to corticosteroid therapy may be less effective. However they are considered safe to administer.(1) Many clinicians consider a dose equivalent to either 2 mg/kg of body weight or a total of 20 mg/day of prednisone as sufficiently immunosuppressive to raise safety concerns about live-virus vaccines.(1) Immunization procedures may be undertaken in patients receiving corticosteroids when the therapy is short term (less than 2 weeks); low to moderate dose; long-term, alternate-day treatment with short-acting preparations; maintenance physiologic doses (replacement therapy); or administered topically (skin or eyes), by aerosol, or by intra-articular, bursal, or tendon injection.(1) |
ACTHAR, ACTHAR SELFJECT, ADRENOCORTICOTROPHIC HORMONE, ALDOSTERONE, ALKINDI SPRINKLE, ANUCORT-HC, ANUSOL-HC, BECLOMETHASONE DIPROPIONATE, BETA 1, BETALOAN SUIK, BETAMETHASONE ACETATE MICRO, BETAMETHASONE ACETATE-SOD PHOS, BETAMETHASONE DIPROPIONATE, BETAMETHASONE SOD PHOS-ACETATE, BETAMETHASONE SOD PHOS-WATER, BETAMETHASONE SODIUM PHOSPHATE, BETAMETHASONE VALERATE, BSP 0820, BUDESONIDE, BUDESONIDE DR, BUDESONIDE EC, BUDESONIDE ER, BUDESONIDE MICRONIZED, BUPIVACAINE-DEXAMETH-EPINEPHRN, CELESTONE, CLOBETASOL PROPIONATE MICRO, CORTEF, CORTENEMA, CORTICOTROPHIN, CORTIFOAM, CORTISONE ACETATE, CORTROPHIN, DEFLAZACORT, DEPO-MEDROL, DESONIDE MICRONIZED, DESOXIMETASONE, DESOXYCORTICOSTERONE ACETATE, DEXABLISS, DEXAMETHASONE, DEXAMETHASONE ACETATE, DEXAMETHASONE ACETATE MICRO, DEXAMETHASONE INTENSOL, DEXAMETHASONE ISONICOTINATE, DEXAMETHASONE MICRONIZED, DEXAMETHASONE SOD PHOS-WATER, DEXAMETHASONE SODIUM PHOSPHATE, DEXAMETHASONE-0.9% NACL, DMT SUIK, DOUBLEDEX, EMFLAZA, EOHILIA, FLUDROCORTISONE ACETATE, FLUNISOLIDE, FLUOCINOLONE ACETONIDE, FLUOCINOLONE ACETONIDE MICRO, FLUOCINONIDE MICRONIZED, FLUTICASONE PROPIONATE, FLUTICASONE PROPIONATE MICRO, HEMADY, HEMMOREX-HC, HEXATRIONE, HYDROCORTISONE, HYDROCORTISONE ACETATE, HYDROCORTISONE SOD SUCCINATE, KENALOG-10, KENALOG-40, KENALOG-80, LIDOCIDEX-I, MAS CARE-PAK, MEDROL, MEDROLOAN II SUIK, MEDROLOAN SUIK, METHYLPREDNISOLONE, METHYLPREDNISOLONE AC MICRO, METHYLPREDNISOLONE ACETATE, METHYLPREDNISOLONE SODIUM SUCC, MILLIPRED, MILLIPRED DP, MOMETASONE FUROATE, ORAPRED ODT, ORTIKOS, PEDIAPRED, PREDNISOLONE, PREDNISOLONE ACETATE MICRONIZE, PREDNISOLONE MICRONIZED, PREDNISOLONE SODIUM PHOS ODT, PREDNISOLONE SODIUM PHOSPHATE, PREDNISONE, PREDNISONE INTENSOL, PREDNISONE MICRONIZED, PRO-C-DURE 5, PRO-C-DURE 6, PROCTOCORT, RAYOS, SOLU-CORTEF, SOLU-MEDROL, TAPERDEX, TARPEYO, TRIAMCINOLONE, TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE DIACETATE, TRIAMCINOLONE DIACETATE MICRO, TRILOAN II SUIK, TRILOAN SUIK, UCERIS, VERIPRED 20, ZCORT |
| Non-Live or Non-Replicating Vaccines/Etrasimod SEVERITY LEVEL: 3-Moderate Interaction: Assess the risk to the patient and take action as needed. MECHANISM OF ACTION: Etrasimod is an immunosuppressant and may alter the immune system's response to vaccines.(1) CLINICAL EFFECTS: Administration of a vaccine during and for up to 5 weeks after discontinuation of etrasimod therapy may result in decreased effectiveness of the vaccine. Etrasimod treatment should be paused 5 weeks prior and for 4 weeks after vaccination.(1) PREDISPOSING FACTORS: None determined. PATIENT MANAGEMENT: Ideally, administer vaccines prior to initiating etrasimod therapy. The immune response to non-live vaccines should be monitored in patients receiving etrasimod or who have received etrasimod in the previous 5 weeks. Vaccinations given during and for up to 5 weeks after discontinuation of etrasimod therapy may need to be repeated.(1) The Centers for Disease Control's (CDC) Advisory Committee on Immunization Practices (ACIP) states that non-live vaccines should be used with caution in patients who are severely immunosuppressed. Patients who are vaccinated within the 14 days prior to initiating immunosuppressive therapy should be considered unvaccinated and should be revaccinated at least 3 months after immunosuppressive therapy is discontinued when immune competence is restored.(2) DISCUSSION: Vaccinations may be less effective if administered during and for up to 5 weeks after etrasimod treatment.(1) However they are considered safe to administer. |
VELSIPITY |
| Non-Live or Non-Replicating Vaccines/Ozanimod SEVERITY LEVEL: 3-Moderate Interaction: Assess the risk to the patient and take action as needed. MECHANISM OF ACTION: Ozanimod is an immunosuppressant and may alter the immune system's response to vaccines.(1) CLINICAL EFFECTS: Administration of a vaccine during and for up to 3 months after discontinuation of ozanimod therapy may result in decreased effectiveness of the vaccine. Ozanimod treatment should be paused 3 months prior and for 1 month after vaccination.(1) PREDISPOSING FACTORS: None determined. PATIENT MANAGEMENT: Ideally, administer vaccines prior to initiating ozanimod therapy. The immune response to non-live vaccines should be monitored in patients receiving ozanimod or who have received ozanimod in the previous 3 months. Vaccinations given during and for up to 3 months after discontinuation of ozanimod therapy may need to be repeated.(1) The Centers for Disease Control's (CDC) Advisory Committee on Immunization Practices (ACIP) states that non-live vaccines should be used with caution in patients who are severely immunosuppressed. Patients who are vaccinated within the 14 days prior to initiating immunosuppressive therapy should be considered unvaccinated and should be revaccinated at least 3 months after immunosuppressive therapy is discontinued when immune competence is restored.(2) DISCUSSION: Vaccinations may be less effective if administered during and for up to 3 months after ozanimod treatment.(1) However they are considered safe to administer. |
ZEPOSIA |
| Non-Live or Non-Replicating Vaccines/Ponesimod SEVERITY LEVEL: 3-Moderate Interaction: Assess the risk to the patient and take action as needed. MECHANISM OF ACTION: Ponesimod is an immunosuppressant and may alter the immune system's response to vaccines.(1) CLINICAL EFFECTS: Administration of a vaccine during and for up to 2 weeks after discontinuation of ponesimod therapy may result in decreased effectiveness of the vaccine. Ponesimod treatment should be paused 1-2 weeks prior and for 4 weeks after vaccination.(1) PREDISPOSING FACTORS: None determined. PATIENT MANAGEMENT: Ideally, administer vaccines prior to initiating ponesimod therapy. The immune response to non-live vaccines should be monitored in patients receiving ponesimod or who have received ponesimod in the previous 2 weeks. Vaccinations given during and for up to 2 weeks after discontinuation of ponesimod therapy may need to be repeated.(1) The Centers for Disease Control's (CDC) Advisory Committee on Immunization Practices (ACIP) states that non-live vaccines should be used with caution in patients who are severely immunosuppressed. Patients who are vaccinated within the 14 days prior to initiating immunosuppressive therapy should be considered unvaccinated and should be revaccinated at least 3 months after immunosuppressive therapy is discontinued when immune competence is restored.(2) DISCUSSION: Vaccinations may be less effective if administered during and for up to 2 weeks after ponesimod treatment.(1) However they are considered safe to administer. |
PONVORY |
The following contraindication information is available for IMOVAX RABIES VACCINE (PF) (rabies vaccine, human diploid cell/pf):
Drug contraindication overview.
No enhanced Contraindications information available for this drug.
No enhanced Contraindications information available for this drug.
There are 0 contraindications.
There are 0 severe contraindications.
There are 1 moderate contraindications.
Clinically significant contraindication, where the condition can be managed or treated before the drug may be given safely.
| Moderate List |
|---|
| High fever >101 degrees fahrenheit |
The following adverse reaction information is available for IMOVAX RABIES VACCINE (PF) (rabies vaccine, human diploid cell/pf):
Adverse reaction overview.
No enhanced Common Adverse Effects information available for this drug.
No enhanced Common Adverse Effects information available for this drug.
There are 10 severe adverse reactions.
| More Frequent | Less Frequent |
|---|---|
| None. | None. |
| Rare/Very Rare |
|---|
|
Anaphylaxis Angioedema Bronchospastic pulmonary disease Encephalitis Guillain-barre syndrome Hypersensitivity drug reaction Meningitis Myelitis Skin rash Urticaria |
There are 16 less severe adverse reactions.
| More Frequent | Less Frequent |
|---|---|
|
Abdominal pain with cramps Arthralgia Chills Dizziness Fatigue Fever Headache disorder Induration of skin Injection site sequelae Lymphadenopathy Malaise Myalgia Nausea Pruritus of skin |
None. |
| Rare/Very Rare |
|---|
|
Flu-like symptoms Vomiting |
The following precautions are available for IMOVAX RABIES VACCINE (PF) (rabies vaccine, human diploid cell/pf):
No enhanced Pediatric Use information available for this drug.
Contraindicated
Severe Precaution
Management or Monitoring Precaution
Contraindicated
| None |
Severe Precaution
| None |
Management or Monitoring Precaution
| None |
The manufacturers state that rabies vaccine should be given to pregnant femalesonly if clearly needed. However, because of the potential risks of inadequately treated rabies exposure and because limited data indicate that fetal abnormalities have not been associated with rabies vaccine, the ACIP, CDC, AAP, American College of Obstetricians and Gynecologists (ACOG), and the manufacturers state that pregnancy is not considered a contraindication for postexposure prophylaxis. ACOG recommends that each pregnant female be considered individually and that public health authorities be consulted.
In addition, when a substantial risk of rabies exposure is present, preexposure vaccination may be indicated during pregnancy. Animal reproduction studies have not been performed with HDCV (Imovax(R)) or PCECV (RabAvert(R)) rabies vaccine.
In addition, when a substantial risk of rabies exposure is present, preexposure vaccination may be indicated during pregnancy. Animal reproduction studies have not been performed with HDCV (Imovax(R)) or PCECV (RabAvert(R)) rabies vaccine.
It is not known if antigens contained in rabies vaccine are distributed into milk. The CDC states that use of rabies vaccine in nursing femalesshould follow the same guidelines as other adults. Because inactivated vaccines do not multiply within the body, the ACIP states that they should not pose any unusual problems for nursing females or their infants.
The manufacturer of PCECV (RabAvert(R)) rabies vaccine states that nursing is not a contraindication to rabies postexposure prophylaxis because of the possible consequences of inadequately treated rabies exposure. Preexposure vaccination with the vaccine in nursing femalesmay also be indicated if the risk of rabies exposure is substantial.
The manufacturer of PCECV (RabAvert(R)) rabies vaccine states that nursing is not a contraindication to rabies postexposure prophylaxis because of the possible consequences of inadequately treated rabies exposure. Preexposure vaccination with the vaccine in nursing femalesmay also be indicated if the risk of rabies exposure is substantial.
No enhanced Geriatric Use information available for this drug.
The following prioritized warning is available for IMOVAX RABIES VACCINE (PF) (rabies vaccine, human diploid cell/pf):
No warning message for this drug.
No warning message for this drug.
The following icd codes are available for IMOVAX RABIES VACCINE (PF) (rabies vaccine, human diploid cell/pf)'s list of indications:
| Rabies postexposure prophylaxis | |
| Z20.3 | Contact with and (suspected) exposure to rabies |
| Z23 | Encounter for immunization |
| Rabies vaccination | |
| Z23 | Encounter for immunization |
Formulary Reference Tool